Ionis Pharmaceuticals announces topline results from Essence study of olezarsen

Ionis Pharmaceuticals (IONS) announced topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease. Nearly all the participants were on current standard of care lipid-lowering medicines. The trial met its primary endpoint with a statistically significant placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80 mg and 50 mg monthly doses, respectively. Olezarsen also met all key secondary endpoints in the study. The vast majority of participants reached less than150mg/dL, reflecting a reduction to normal TG levels. Olezarsen demonstrated a favorable safety and tolerability profile in the study. Ionis plans to submit an abstract for presentation at an upcoming scientific conference. Data from the pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen for the treatment of severe hypertriglyceridemia are expected in Q3. Olezarsen demonstrated a favorable safety and tolerability profile in the study. The most common treatment-emergent adverse event that occurred more frequently than placebo in the olezarsen groups was injection site reactions, with the majority being mild in severity.